Q4 2025 Management View Peter Altman, CEO, highlighted that BioCardia now has complete and final data from three clinical trials of CardiAMP cell therapy, with the latest Phase III results presented ...
At the AD/PD 2026, Roche showcased new five-year data from the Phase II PASADENA trial (NCT03100149) involving prasinezumab.
Lyell Immunopharma, Inc. is rated a Buy, with upside contingent on replicating clinical superiority in larger trials. Learn ...
Q4 2025 Earnings Call March 24, 2026 4:30 PM EDTCompany ParticipantsMiranda Benvenuti - Investor Relations ExecutivePeter Altman ...
NÖK Therapeutics, Inc. ('NÖK” or the 'Company”), a clinical-stage biotechnology company advancing autologous Natural Killer ( ...
Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (pPotential 2X treatment benefit compared to 15% and 22% ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the National Comprehensive ...
A powerful new real-world data platform could transform how scientists predict and understand Alzheimer's disease and ...
The introduction of highly effective direct-acting antivirals has transformed the HCV treatment landscape, enabling cure ...
A powerful new real-world data platform could transform how scientists predict and understand Alzheimer's disease and ...
Morning Overview on MSN
New Apogee Therapeutics data reveal long-acting eczema drug cuts flares with fewer shots
Apogee Therapeutics is advancing APG777, an experimental antibody designed to treat moderate-to-severe atopic dermatitis with far fewer injections than existing biologics. Early clinical data show the ...
Copilot Health stores users’ health data separately from nonmedical chat logs. Microsoft says that it encrypts the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results